pegfilgrastim   Click here for help

GtoPdb Ligand ID: 6969

Synonyms: Neulasta®
Approved drug
pegfilgrastim is an approved drug (FDA and EMA (2002))
Compound class: Peptide
Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim [1].

Biosimilars:
NameTrade nameCompanyClinical phaseIndications
pegfilgrastim-jmbd; MYL-1401HFulphilaMylanApproved (2018 FDA & EMA)As per reference agent [2]
 PelgrazAccordApproved (2018 EMA)As per reference agent
 PelmegMundipharma (developed by Cinfa Biotech)Approved (2018 EMA)As per reference agent
 pegfilgrastim MundipharmaMundipharma Approved (2019 EMA)As per reference agent
pegfilgrastim-cbqv; CHS-1701UdenycaERA Consulting; Coherus BioSciencesApproved (2018 FDA & EMA)As per reference agent
USV pegfilgrastimGrasustekJuta PharmaApproved (2019 EMA)As per reference agent
pegfilgrastim-bmez; LA-EP2006ZiextenzoSandozApproved (2018 EMA, 2019 FDA)As per reference agent
pegfilgrastim-apgf; PF-06881894NyvepriaPfizerApproved (2020 FDA)As per reference agent
pegfilgrastim-fpgk; MSB11455StimufendFresenius KabiApproved (2022 FDA & EMA)As per reference agent
pegfilgrastim-pbbkFylnetraAmneal PharmaceuticalsApproved (2022 FDA)As per reference agent
Classification Click here for help
Compound class Peptide
Approved drug? Yes (FDA and EMA (2002))
Approved drug? Yes. FDA (2002)  |  EMA (2002)
International Nonproprietary Names Click here for help
INN number INN
8114 pegfilgrastim
Synonyms Click here for help
Neulasta®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 616
Other databases
CAS Registry No. 208265-92-3 (source: Scifinder)
ChEMBL Ligand CHEMBL1201568
DrugBank Ligand DB00019
GtoPdb PubChem SID 178103549
Search PubMed clinical trials pegfilgrastim
Search PubMed titles pegfilgrastim
Search PubMed titles/abstracts pegfilgrastim
Wikipedia Pegfilgrastim